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A standardised methodology for a combined point 
prevalence survey (PPS) on healthcare-associated 
infections (HAIs) and antimicrobial use in European 
acute care hospitals developed by the European Centre 
for Disease Prevention and Control was piloted across 
Europe. Variables were collected at national, hospital 
and patient level in 66 hospitals from 23 countries. A 
patient-based and a unit-based protocol were avail-
able. Feasibility was assessed via national and hos-
pital questionnaires. Of 19,888 surveyed patients, 
7.1% had an HAI and 34.6% were receiving at least one 
antimicrobial agent. Prevalence results were highest 
in intensive care units, with 28.1% patients with HAI, 
and 61.4% patients with antimicrobial use. Pneumonia 
and other lower respiratory tract infections (2.0% 
of patients; 95% confidence interval (CI): 1.8–2.2%) 
represented the most common type (25.7%) of HAI. 
Surgical prophylaxis was the indication for 17.3% of 
used antimicrobials and exceeded one day in 60.7% of 
cases. Risk factors in the patient-based protocol were 
provided for 98% or more of the included patients and 
all were independently associated with both pres-
ence of HAI and receiving an antimicrobial agent. The 
patient-based protocol required more work than the 
unit-based protocol, but allowed collecting detailed 
data and analysis of risk factors for HAI and antimicro-
bial use.
Introduction
Healthcare-associated infections (HAIs) and antimi-
crobial resistance are well known major public health 
threats. The European Centre for Disease Prevention 
and Control (ECDC) proposed in 2008 that the total 
burden of HAIs should be measured regularly and in a 
standardised manner throughout the European Union 
(EU) [1]. The initial steps towards standardisation of 
surveillance of HAIs in Europe had been carried out 
on surgical site infections and infections in intensive 
care units by the ‘Hospitals in Europe Link for Infection 
Control through Surveillance (HELICS)’ project, from 
2000 to 2003 [2-6].
Subsequently, HELICS implemented standardised sur-
veillance of HAIs in 2004 and 2005, and later as part 
of the ‘Improving Patient Safety in Europe (IPSE)’ net-
work from 2005 to 2008 [7] which was transferred to 
ECDC in July 2008. Continuous surveillance, especially 
prospective active surveillance, is the gold standard 
[8]. However, repeated point prevalence surveys (PPSs) 
represent a more feasible alternative for hospital-wide 
surveillance of all HAIs, while still allowing the estima-
tion of disease burden by HAIs in acute hospitals, and 
helping to prioritise areas requiring interventions [9]. 
Based on a review of 30 national or multicentre PPSs 
in 19 countries that had been carried out between 1996 
and 2007 and included a total of 837,450 patients, 
ECDC estimated in 2008 the prevalence of HAIs in EU 
acute care hospitals to be on average of 7.1% [1].
However, major methodological differences between 
these PPSs made comparison between countries 
impossible [1,10-13]. When coordination of the IPSE 
network was transferred to ECDC in July 2008, ECDC 
recommended that surveillance in the EU should 
include all types of HAIs. Subsequently, the ECDC pre-
pared a protocol for a PPS of HAIs in acute care hospi-
tals, which was finalised in March 2011 [14]. 
Although most antimicrobials are prescribed in the 
community [15], the selective pressure they exert is 
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much higher in hospitals, where the proportion of 
patients receiving antimicrobial agents is much higher 
there than in the community [16]. This is considered 
to be the main reason why microorganisms isolated 
from hospital infections show more resistant profiles 
than microorganisms from community infections [17]. 
Various hospital PPSs on antimicrobial use were car-
ried out in the last three decades [18-22]. Also these 
PPS varied greatly in aims, protocols and populations 
surveyed, thus making comparison of their results 
difficult. The ‘European Surveillance of Antimicrobial 
Consumption (ESAC)’ project initiated standardisa-
tion of the methodology for measuring antimicrobial 
consumption across Europe [23-26]. This methodology 
has proven feasible and reliable [24,25,27]. In view 
of the transition of the ESAC network to ECDC in July 
2011, the ESAC methodology for PPS of antimicrobial 
use was integrated as part of an ECDC protocol for PPS 
of HAIs and antimicrobial use in acute care hospitals. 
Combined PPSs of HAIs and antimicrobial use had also 
previously been carried out in different populations 
[28-32], but again with large methodological differ-
ences between surveys. 
The main aim of this ECDC pilot PPS was to test a 
common European methodology for PPSs of HAIs and 
antimicrobial use in acute care hospitals before its 
implementation across the EU, with the specific objec-
tives to estimate the total burden of HAIs and antimicro-
bial use and disseminate the results at local, regional, 
national and EU level. The ECDC pilot PPS protocol met 
the objectives of the Council Recommendation of 9 June 
2009 on patient safety, including the prevention and 
control of HAIs (2009/C 151/01), and specifically arti-
cle II.8.c of this recommendation, i.e. “to establish or 
strengthen active surveillance at institution, regional 
and national level” [33]. In addition, the ECDC pilot PPS 
also met the objectives of Council Recommendation of 
15 November 2001 on the prudent use of antimicrobial 
agents in human medicine (2002/77/EC) [34].
Methods
Participating countries and hospitals
In January 2010, ECDC invited all national contact 
points for HAI surveillance and/or experts designated 
as national expert for the ECDC PPS to participate in 
the pilot PPS study and enter at least one institution 
qualified as acute care hospital according to national 
definitions. Two or more hospitals per country were 
preferred to allow testing of both the patient-based 
(’standard’) and unit-based (’light’) version of the pro-
tocol in the same country. In total, 23 countries (22 EU 
Member States and one EU enlargement country) par-
ticipated in the survey with 66 hospitals and including 
19,888 patients. 
The number of hospitals per country was: Belgium (n=7 
hospitals), Bulgaria (n=2), Croatia (n=2), Cyprus (n=3), 
Czech Republic (n=2), Estonia (n=2), Finland (n=16), 
France (n=3), Germany (n=1), Greece (n=1), Hungary 
(n=2), Italy (n=4), Latvia (n=2), Lithuania (n=3), 
Luxembourg (n=1), Malta (n=1), Poland (n=1), Portugal 
(n=2), Romania (n=1), Slovakia (n=2), Slovenia (n=2), 
Spain (n=5), and the United Kingdom, Scotland (n=1).
The national contact points acted as national PPS 
coordinators and invited hospitals to participate on 
a voluntary basis. As this was a pilot survey, we did 
not aim for a representative sample of hospitals in the 
countries. It was recommended to include both large 
and small hospitals in order to test the feasibility of the 
protocol in different settings. Information on the size 
and type (primary, secondary, tertiary and specialised) 
of each hospital was collected through a specific hos-
pital questionnaire. National questionnaires were used 
to collect data on the number of acute care hospitals 
and beds for the entire country and by hospital type. 
Case definitions
European case definitions for HAIs were used where 
these had been developed previously by HELICS or 
other European projects [35-38], whereas case defi-
nitions from the National Healthcare Safety Network 
(NHSN, formerly NNIS) at the United States Centers 
for Disease Control and Prevention (CDC) were used 
otherwise [39,40]. In the HAI section, data on microor-
ganisms and the respective resistant phenotype were 
collected. Only results that were already available on 
the date of the survey were included. 
For the purposes of this protocol, an infection was 
defined as active on the day of the survey when:
1. signs and symptoms were present on the date of the 
survey; 
OR
 2. signs and symptoms were no longer present but the 
patient was still receiving treatment for that infection 
on the date of the survey. In this case, the symptoms 
and signs occurring from the start of treatment until 
the date of the survey were checked to ascertain that 
the infection matched one of the case definitions of 
HAI.
An active infection was defined as healthcare-associ-
ated (associated to acute care hospital stay only, for 
the purpose of this protocol) when: 
1. the onset of the signs and symptoms was on Day 3 
of the current admission or later (with Day 1 the day of 
admission);
 OR 
2. the signs and symptoms were present at admission 
or became apparent before Day 3, but the patient had 
been discharged from an acute care hospital less than 
two days before admission; 
OR 
3. the signs and symptoms of an active surgical site 
infection were present at admission or started before 
Day 3, and the surgical site infection occurred within 
30 days of a surgical intervention (or in the case of 
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surgery involving an implant, a deep or organ/space 
surgical site infection that developed within a year of 
the intervention); 
OR 
4. the signs and symptoms of a Clostridium difficile 
infection were present at admission or started before 
Day 3, with the patient having been discharged from 
an acute care hospital less than 28 days before the cur-
rent admission.
For antimicrobial use, the Anatomical Therapeutic 
Chemical (ATC) classification system of the World Health 
Organization Collaborating Centre for Drug Statistics 
Methodology was used [41]. Antimicrobial agents for 
systemic use within the ATC groups A07AA (intestinal 
anti-infectives), D01BA (dermatological antifungals for 
systemic use), J01 (antibacterials for systemic use), J02 
(antimycotics for systemic use), J04AB02 (rifampicin) 
and P01AB (nitroimidazole-derived antiprotozoals) 
were included. Antiviral agents and antimicrobials for 
the treatment of tuberculosis were not included.
As in the former ESAC hospital PPS protocol [23-26], 
antimicrobial treatment was recorded if, at the time 
of survey, the antimicrobial agent was still prescribed 
on the treatment chart. In the case of surgical prophy-
laxis, any single dose of an antimicrobial agent given 
within the 24-hour period before 8:00 am on the day of 
the survey was recorded. This time window for surgical 
prophylaxis allowed making the distinction between 
single dose prophylaxis, one day prophylaxis, or pro-
phylactic doses given over more than one day.
Data collection and inclusion criteria
Two data collection protocols were available for use by 
participating hospitals. The first was patient-based: 
Denominator data, including risk factors, were collected 
for each individual patient irrespective of whether 
the patient had a HAI and/or received antimicrobials. 
The patient form for this protocol also included more 
detailed information, such as the presence of invasive 
devices, the specialty area of the patient’s disease or 
consultant in charge of the patient and the McCabe 
score (the McCabe score classifies the severity of 
underlying medical conditions) [42]. The second proto-
col was unit-based: Denominator data were aggregated 
at ward level, and a patient form was used only for 
patients with a HAI and/or receiving antimicrobials. For 
both protocols, data were also collected at both ward 
level (ward name and specialty) and hospital level, 
including hospital type, size and whether or not any 
wards were excluded from the survey.
Each participating hospital had to choose one of 
the two data collection protocols. For each ward, all 
patients registered on the ward census before 8:00 am 
and not discharged from the ward at the time of the 
survey were assessed. Patients who were temporarily 
absent from the ward (e.g. for medical imaging, endos-
copy, surgery) were included in the survey. Day admis-
sions, outpatients (including patients attending the 
hospital for haemodialysis) and patients at the Accident 
and Emergency department were excluded. In addition, 
given that the agreed objective of the EU-wide ECDC 
PPS was to estimate the burden of HAIs and antimi-
crobial use in acute care hospitals only, long-term care 
units in acute care hospitals were excluded from the 
survey; however, long-term patients within an acute 
care ward were included. It was recommended that 
each participating hospital should include all eligible 
patients in the survey. Despite this recommendation, 
five of the 66 hospitals excluded one or several wards 
that were eligible for inclusion, because the hospital 
staff considered that being exhaustive was not needed 
for a pilot study.
The ECDC pilot PPS protocol recommended that person-
nel experienced in reading patient charts/notes and in 
identifying HAIs (e.g. infection control professionals, 
clinical microbiologists, infectious disease physicians) 
should act as survey team leaders in the hospitals. To 
obtain better information, collaboration with the clini-
cal team in charge of patient care was recommended 
rather than exclusively reading the patient chart/notes 
and laboratory results. The number and type of health-
care workers (HCWs) performing the PPS in the hospi-
tal was assessed by questionnaire.
Data collectors in the hospital were trained by the 
national PPS coordinators to become familiar with 
the protocol and case definitions. Training material in 
English language was provided by ECDC through a con-
tract with the Health Protection Agency, London (con-
tract ECD.1842).
Time window
The ECDC pilot PPS had to be carried out any time 
between May and October 2010. The ideal duration of 
a ‘point’ prevalence survey is a single day but this was 
not feasible for the majority of participants due to the 
size of the hospital and/or the lack of trained person-
nel. To ensure feasibility of the survey, the maximum 
total time allowed to complete data collection in each 
hospital was three weeks and preferably not more than 
two weeks. Each individual ward, and if possible each 
respective department (e.g. all medical wards), had to 
be surveyed on the same day.
Data entry 
Each country was free to organise its own system for 
data entry and processing, as long as all variables 
were collected in accordance with the ECDC methodol-
ogy. It was not possible for a hospital to use a mixture 
of the patient-based and unit-based protocols. Most 
hospitals entered their data directly into an adapted 
version of the ESAC WebPPS located on the server 
of the University of Antwerp [24,25]. Only one coun-
try (Slovenia), participating with two hospitals, used 
its local software, whilst Belgium used the WebPPS 
installed on the server of the Belgian Scientific Institute 
for Public Health (WIV-ISP) in Brussels. Belgian 
data were uploaded on the WIV-ISP server and were 
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later incorporated into the European data set at the 
University of Antwerp. Data from Slovenia were con-
verted by ECDC and then transferred to the University 
of Antwerp for incorporation into the central database.
Feasibility and workload
An additional feasibility questionnaire was sent to the 
national contact points of the 23 participating countries 
and to the corresponding 66 hospital contact points. 
At the national level, we requested information about 
whether a list of hospitals by type (primary, second-
ary, tertiary and specialised) and size was available, 
thus assessing the feasibility of a systematic sam-
pling design using these variables in future surveys. 
National contact points were also asked to give any 
other feedback regarding the feasibility of obtaining a 
representative sample of hospitals in their country. In 
addition, data about the workload needed for training, 
data collection and data entry were requested both at 
the national and hospital level. The number and type of 
HCWs involved in the survey were also collected. 
Data analysis
Data were analysed at the University of Antwerp and at 
ECDC using Stata 10.1 (StataCorp Texas, US). Binomial 
exact confidence limits were calculated where appro-
priate. Risk factor analysis was performed separately 
for HAIs and for antimicrobial use using multiple logis-
tic regression. Presence of a peripheral and central 
vascular catheter were excluded from the multiple 
logistic regression model since the time relationship 
between insertion of a catheter and start of parenteral 
antimicrobial use cannot be deduced from the protocol. 
In both models, p values below 0.05 were considered 
as statistically significant. Individual hospital reports 
(Microsoft Excel spreadsheets) summarising the hospi-
tal’s prevalence figures, compared to the aggregated 
prevalence figures of all participating hospitals in the 
country, were produced by ECDC using Stata 10.1 and 
sent to the national contact points for further distribu-
tion and feedback to the hospital contact points. We 
did not receive any feedback from the hospitals that 
these reports were not concordant with local hospital 
data.
Results
A total of 19,888 patients from 66 hospitals in 23 coun-
tries were included in the ECDC pilot PPS. Fifty hospi-
tals used the patient-based protocol and 16 hospitals 
used the unit-based protocol.
Hospital characteristics were available for 65 hospi-
tals. University or other teaching hospitals (defined 
as ’tertiary’ hospitals in the protocol) represented 
52.3% of participating hospitals, secondary hospitals 
24.6%, primary hospitals 15.4% and specialised hos-
pitals 7.7%, with an average hospital size of 614 beds, 
431 beds, 215 beds and 300 beds, respectively. The 
overall average hospital size in the study sample was 
483 beds (median: 400 beds). At national level, only 
13 countries (representing 29 hospitals in the study 
sample) were able to provide national numbers of hos-
pitals by type. Tertiary hospitals represented 7.7% of 
all acute care hospitals in these countries, secondary 
hospitals 31.1%, primary hospitals 49.3% and special-
ised hospitals 11.9%. The total number of hospitals 
in these 13 countries was 2,609 with on average 298 
Table 1
Prevalence of healthcare-associated infections and antimicrobial use in surveyed patients, by specialty, during the ECDC 
pilot point prevalence survey, 2010 (n=19,888)
Specialty 
Surveyed patients Patients with HAIa Patients with antimicrobial useb
nc %d nc %e nc %e
Surgery 6,653 33.5 518 7.8 2,584 38.8
Medicine 7,833 39.4 505 6.4 2,888 36.9
Paediatrics 1,024 5.1 38 3.7 310 30.3
Intensive care 915 4.6 257 28.1 562 61.4
Obstetrics and Gynaecology 1,711 8.6 32 1.9 313 18.3
Geriatrics 502 2.5 33 6.6 117 23.3
Psychiatry 828 4.2 2 0.2 18 2.2
Other/mixed 422 2.1 23 5.5 83 19.7
All specialties 19,888 100 1,408 7.1 6,875 34.6
ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection.
a  Patients with a least one HAI.
b  Patients receiving at least one antimicrobial agent.
c  Number of patients in category.     
d  Percentage of total (column percent). 
e  Percentage within category (category percent).
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beds (median: 261 beds), for a total population of 160 
million inhabitants in 2010. 
Healthcare-associated infections
Overall, 7.1% patients had at least one HAI, ranging 
from 0.2% in psychiatry to 28.1% in intensive care 
departments (Table 1). The prevalence of HAIs was 
5.8% in primary hospitals, 6.3% in secondary hospi-
tals, 7.4% in tertiary hospitals and 7.8% in specialised 
hospitals.
The most common type of HAI was pneumonia and 
other lower respiratory tract infections, representing 
25.7% of all reported HAIs (Table 2). The second most 
frequently reported type of HAI was surgical site infec-
tion (18.9%), followed by urinary tract infection (17.2%), 
bloodstream infection (14.2%) and gastro-intestinal 
infection (7.8%). Clostridium difficile infections repre-
sented 1.4% of all HAIs. On average, there were 1.09 
HAIs per infected patient (or a total of 1,531 HAIs in 
1,408 patients with HAI). The median length of stay 
before onset of HAI acquired during the current hospi-
talisation (n=1,159) was 12 days (range: 4–65 days). Of 
372 (24%) HAIs present at admission, 58% were associ-
ated with a previous stay in the same hospital.
For 59.1% of the HAIs, a positive microbiology result 
was available, ranging from 40.3% for gastro-intestinal 
infections to 94.0% in bloodstream infections (Table 
3).
The most commonly isolated groups of microorgan-
isms were Gram-negative non-Enterobacteriaceae in 
pneumonia (36.5%), Enterobacteriaceae in urinary tract 
infections (63.8%) and Gram-positive cocci in surgical 
site infections (54.3%). Overall, the most commonly 
isolated microorganism was Escherichia coli (15.2% 
overall, and 37.1% in urinary tract infections), followed 
by Staphylococcus aureus (12.1% overall and 21.5% in 
surgical site infections).
Carbapenem resistance was reported in 3.2% of 
Enterobacteriaceae, 23.4% of Pseudomonas aerugi-
nosa and 20.4% of Acinetobacter spp. The percentage 
of meticillin-resistant S. aureus (MRSA) was 34.2% and 
that of glycopeptide-resistant Enterococcus spp. was 
5.4%. 
Antimicrobial use
A total of 6,875 patients (34.6%) received at least one 
antimicrobial agent at the time of the survey, rang-
ing from 2.2% in psychiatry to 61.4% in intensive care 
departments (Table 1). The prevalence of antimicrobial 
use was 36.2% in primary hospitals, 32.1% in second-
ary hospitals, 35.7% in tertiary hospitals and 28.7% 
in specialised hospitals. Analysing the antimicrobial 
agents used by main indication (treatment, surgical 
prophylaxis and medical prophylaxis) revealed dif-
ferences in the use of different antimicrobial classes 
(Table 4). 
Pneumonia or other lower respiratory tract infection 
was the most common indication (29.2%) for antimicro-
bial treatment, and accounted for 31.6% of intentions 
for treatment of community infection, and 24.8% of 
intentions for treatment of hospital infection.
The most widely used antimicrobial agents at ATC 4th 
level were combinations of penicillins with beta-lacta-
mase inhibitors (16.3%), mainly for treatment intention 
(18.0%). For surgical prophylaxis, first- and second-
generation cephalosporins were mostly chosen: 26.8% 
and 20.0%, respectively. For medical prophylaxis, fluo-
roquinolones, primarily ciprofloxacin, were the most 
widely used antimicrobial agents.
Table 5 summarises the indications for antimicro-
bial use, their route of administration and whether 
the reason for antimicrobial use was indicated on the 
patient chart. Community infection was the most com-
mon treatment intention (41.3%), followed by hospital 
infection (24.0%). Surgical prophylaxis (17.3%) was 
prolonged for more than one day in 60.7% of cases. 
Medical prophylaxis accounted for 13.5% of antimicro-
bial use. The parenteral route of administration was 
used for 71.9% of administered antimicrobial agents. 
A reason was included in the chart of 69.3% of the 
patients on antimicrobials (Table 5). 
Risk factors
Data from the 50 hospitals that used the patient-based 
protocol, including patient characteristics and risk 
factors, are shown in Table 6. Using multiple logis-
tic regression, the presence of an HAI was indepen-
dently associated with age (highest adjusted odds 
ratio in children under five years-old, p<0.001), male 
sex (p<0.05), length of stay before onset of HAI (p for 
trend<0.001), the McCabe score (p for trend<0.001), 
the number of invasive devices (urinary catheter and 
intubation) before onset of infection (p for trend<0.001) 
and surgery since admission (p<0.001). Antimicrobial 
use was independently associated with age (highest 
adjusted odds ratio in the age category 1–4 years, 
p<0.001), male sex (p<0.001), the McCabe score (p for 
trend<0.001), the number of invasive devices (urinary 
catheter and intubation, p for trend <0.001), length of 
stay in the hospital (p for trend<0.05) and surgery since 
admission (p<0.001). 
Feasibility
Thirteen countries (Belgium, Bulgaria, Cyprus, Estonia, 
France, Greece, Italy, Lithuania, Malta, Portugal, 
Romania, Slovakia and Spain) responded to the national 
feasibility questionnaire. Fifty hospitals responded to 
the hospital feasibility questionnaire. 
Overall, the average number of HCW involved in data 
collection, excluding ward staff, was six, with a maxi-
mum of 21. In five hospitals, one single HCW was 
involved in the data collection process. Ward staff was 
involved in 20 hospitals. On average per hospital, 3,7 
different types of HCW were involved in the survey for 
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Table 2
Prevalence of healthcare-associated infections and antimicrobial use in surveyed patients, by specialty, during the ECDC 
pilot point prevalence survey, 2010 (n=19,888)
Type of infection 
HAIs
Antimicrobial use (treatment only)a
All treatment 
intentionsb
Treatment intended 
for community 
infection
Treatment intended 
for hospital 
n 
patientsc
% 
patients
[95% CI]d
n 
HAIse
Relative 
% HAIs f
n
intentions
Relative 
%
n
intentions
Relative 
%
n
intentions
Relative 
%
Pneumonia or other 
lower respiratory tract 
infection
392 2.0 [1.8–2.2] 394 25.7 1,328 29.2 922 31.6 382 24.8
Surgical site infection 290 1.5 [1.3–1.6] 290 18.9 –
g –g –g –g –g –g
Urinary tract infection 263 1.3 [1.2–1.5] 264 17.2 679 14.9 412 14.1 237 15.4
Bloodstream infection 
(BSI)h 216
1.1 
[0.9–1.2] 217 14.2 219 4.8 67 2.3 145 9.4
Gastrointestinal 
infection 118
0.6 
[0.5–0.7] 119 7.8 593 13.0 466 16.0 117 7.6
Skin and soft tissue 
infection 59
0.3 
[0.2–0.4] 59 3.9 646 14.2 357 12.2 279 18.1
Bone or joint 
infection 38
0.2 
[0.1–0.3] 39 2.5 154 3.4 92 3.2 60 3.9
Eye, ear, nose or 
mouth infection 47
0.2 
[0.2–0.3] 47 3.1 211 4.6 170 5.8 41 2.7
Systemic infectionh 40 0.2 [0.1–0.3] 40 2.6 668 14.7 318 10.9 334 21.7
Cardiovascular 
system infection 26
0.1 
[0.1–0.2] 26 1.7 76 1.7 40 1.4 36 2.3
Central nervous 
system infection 15
0.1 
[0.0–0.1] 15 1.0 67 1.5 54 1.8 12 0.8
Catheter-related 
infections without 
bloodstream infection
11 0.1 [0.0–0.1] 11 0.7 –
g –g –g –g –g –g
Reproductive tract 
infection 10
0.1 
[0.0–0.1] 10 0.7 65 1.4 49 1.7 16 1.0
Missing/unknown 0 NA NA NA 65 1.4 39 1.3 25 1.6
Total 1,408  7.1 [6.7–7.5] 1,531 100 4,552 100 2,919 100 1,539 100
CI: confidence interval; ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection; NA: not applicable.
a  This table does not include antimicrobials used for prophylaxis or for unknown indications (shown in Table 5). 
b  The category “Treatment intended for infections acquired in long-term care facilities” represented 2.0% of all treatment intentions and is 
not shown in the table.
c  Number of patients with HAI (site-specific number)
d  Percentage of patients with HAI (site-specific prevalence)                                                                                                       
e  Number of HAIs.
f  Percentage of total number of HAIs (relative percentage)                                                                                                                                                                                                                
g  For used antimicrobials, the types of infection ‘surgical site infection’ and ‘catheter-related infection without bloodstream infection’ were 
not specifically recorded and could be included within the category ‘skin and soft tissue infection’.
h  Includes catheter-related infections with positive blood culture, and neonatal bloodstream infections and clinical sepsis. For used 
antimicrobials, some bloodstream infections (bacteraemia) may have been included in the category ‘systemic infection’.                       
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Table 3
Distribution of microorganisms isolated in healthcare-associated infections, by main type of infection, ECDC pilot point 
prevalence survey, 2010 (n=1,165) 
All types of 
infection
Pneumonia or 
other lower 
respiratory tract 
infection
Surgical site 
infection
Urinary tract 
infection
Bloodstream 
infection
Gastrointestinal 
infection
n (%) n (%) n (%) n (%) n (%) n (%)
HAIs and microorganisms
HAIs, total 1,531 (100) 394 (25.7) 290 (18.9) 264 (17.2) 200 (13.1) 119 (7.8)
HAIs with microorganisms 905 (59.1) 191 (48.5) 172 (59.3) 187 (70.8) 188 (94.0) 48 (40.3)
Microorganisms, total 1,165 (100) 249 (100) 247 (100) 210 (100) 228 (100) 65 (100)
Major groups of microorganisms
Gram-positive cocci 410 (35.2) 46 (18.5) 134 (54.3) 39 (18.6) 95 (41.7) 21 (32.3)
Enterobacteriaceae 404 (34.7) 80 (32.1) 58 (23.5) 134 (63.8) 79 (34.7) 18 (27.7)
Gram-negative bacteria, 
non-Enterobacteriaceae 226 (19.4) 91 (36.5) 36 (14.6) 29 (13.8) 30 (13.2) 7 (10.8)
Fungi 69 (5.9) 23 (9.2) 5 (2.0) 7 (3.3) 17 (7.5) 4 (6.2)
Top 15 microorganisms (accounting for (92.4% of total number microorganisms) 
Escherichia coli 177 (15.2) 24 (9.6) 29 (11.7) 78 (37.1) 29 (12.7) 10 (15.4)
Staphylococcus aureus 141 (12.1) 26 (10.4) 53 (21.5) 2 (1.0) 26 (11.4) 5 (7.7)
Pseudomonas aeruginosa 131 (11.2) 44 (17.7) 24 (9.7) 21 (10.0) 17 (7.5) 6 (9.2)
Enterococcus spp. 114 (9.8) 4 (1.6) 33 (13.4) 32 (15.2) 21 (9.2) 11 (16.9)
Coagulase-negative 
staphylococci 97 (8.3) 3 (1.2) 33 (13.4) 3 (1.4) 38 (16.7) 1 (1.5)
Klebsiella spp. 94 (8.1) 22 (8.8) 7 (2.8) 30 (14.3) 25 (11.0) 3 (4.6)
Candida spp. 56 (4.8) 15 (6.0) 3 (1.2) 6 (2.9) 16 (7.0) 3 (4.6)
Enterobacter spp. 49 (4.2) 13 (5.2) 10 (4.0) 6 (2.9) 10 (4.4) 1 (1.5)
Acinetobacter spp. 49 (4.2) 18 (7.2) 5 (2.0) 5 (2.4) 9 (4.0) 1 (1.5)
Streptococcus spp. 45 (3.9) 13 (5.2) 11 (4.5) 2 (1.0) 4 (1.8) 4 (6.2)
Proteus spp. 35 (3.0) 5 (2.0) 6 (2.4) 15 (7.1) 4 (1.8) 0 (0)
Anaerobic bacilli 24 (2.1) 1 (0.4) 5 (2.0) 0 (0) 5 (2.2) 11 (16.9)
Serratia spp. 17 (1.5) 11 (4.4) 1 (0.4) 0 (0) 5 (2.2) 0 (0)
Other Enterobacteriaceae 17 (1.5) 3 (1.2) 0 (0) 1 (0.5) 4 (1.8) 3 (4.6)
Stenotrophomonas maltophilia 16 (1.4) 11 (4.4) 3 (1.2) 0 (0) 1 (0.4) 0 (0)
Citrobacter spp. 15 (1.3) 2 (0.8) 5 (2.0) 4 (1.9) 2 (0.9) 1 (1.5)
ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection.
The table only shows details for the main infection types. The total also includes all other HAI types.
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Table 4
Distribution of antimicrobial agents (ATC 4th and 5th levels) by main indication for use, ECDC pilot point prevalence 
survey, 2010 (n=9,588 antimicrobial agents)
All indications Treatment Surgical prophylaxis
Medical 
prophylaxis
n (%) n (%) n (%) n (%)
Antimicrobial agents, total 9,588 (100) 6,365 (100) 1,654 (100) 1,293 (100)
Top antimicrobial agents at ATC 4th level (accounting for 93.1% of use)
 Combinations of penicillins, incl. beta-lactamase inhibitors (J01CR) 1,566 (16.3) 1,147 (18.0) 217 (13.1) 145 (11.2)
 Fluoroquinolones (J01MA) 1,293 (13.5) 948 (14.9) 133 (8.0) 168 (13.2)
 Second-generation cephalosporins (J01DC) 900 (9.4) 475 (7.5) 330 (20.0) 76 (5.9)
 Third-generation cephalosporins (J01DD) 701 (7.3) 521 (8.2) 94 (5.7) 67 (5.2)
 First-generation cephalosporins (J01DB) 599 (6.2) 121 (1.9) 444 (26.8) 23 (1.8)
 Carbapenems (J01DH) 583 (6.1) 503 (7.9) 25 (1.5) 37 (2.9)
 Imidazole derivatives (J01XD) 494 (5.2) 278 (4.4) 151 (9.1) 51 (3.9)
 Glycopeptide antibacterials (J01XA) 449 (4.7) 365 (5.7) 41 (2.5) 31 (2.4)
 Aminoglycosides (J01GB) 427 (4.5) 277 (4.4) 72 (4.4) 69 (5.3)
 Triazole derivatives (J02AC) 424 (4.4) 246 (3.9) 11 (0.7) 153 (11.8)
 Penicillins, extended spectrum without anti-pseudomonal activity (J01CA) 289 (3.0) 200 (3.1) 18 (1.1) 65 (5.0)
 Combinations of sulfonamides and trimethoprim, incl. derivatives (J01EE) 252 (2.6) 70 (1.1) 7 (0.4) 163 (12.6)
 Lincosamides (J01FF) 232 (2.4) 183 (2.9) 38 (2.3) 11 (0.9)
 Macrolides (J01FA) 185 (1.9) 144 (2.3) 4 (0.2) 26 (2.0)
 Beta-lactamase-resistant penicillins (J01CF) 160 (1.7) 138 (2.2) 16 (1.0) 5 (0.4)
 Nitroimidazole derivatives (P01AB) 134 (1.4) 102 (1.6) 17 (1.0) 9 (0.7)
 Beta-lactamase-sensitive penicillins (J01CE) 133 (1.4) 90 (1.4) 9 (0.5) 32 (2.5)
 Other antibacterials (J01XX) 102 (1.1) 80 (1.3) 4 (0.2) 11 (0.9)
 Top antimicrobial agents at ATC 5th level (accounting for 70.8% of use)
 Amoxicillin and enzyme inhibitor (J01CR02) 1,045 (10.9) 696 (10.9) 193 (11.7) 104 (8.0)
 Cefuroxime (J01DC02) 866 (9.0) 466 (7.3) 318 (19.2) 63 (4.9)
 Ciprofloxacin (J01MA02) 844 (8.8) 607 (9.5) 100 (6.0) 113 (8.7)
 Metronidazole (J01XD01) 493 (5.1) 277 (4.4) 151 (9.1) 51 (3.9)
 Cefazolin (J01DB04) 473 (4.9) 57 (0.9) 396 (23.9) 12 (0.9)
 Piperacillin and enzyme inhibitor (J01CR05) 432 (4.5) 374 (5.9) 19 (1.1) 36 (2.8)
 Ceftriaxone (J01DD04) 396 (4.1) 282 (4.4) 52 (3.1) 47 (3.6)
 Vancomycin (parenteral) (J01XA01) 376 (3.9) 310 (4.9) 36 (2.2) 26 (2.0)
 Meropenem (J01DH02) 375 (3.9) 322 (5.1) 9 (0.5) 29 (2.2)
 Fluconazole (J02AC01) 319 (3.3) 201 (3.2) 11 (0.7) 96 (7.4)
 Levofloxacin (J01MA12) 310 (3.2) 246 (3.9) 13 (0.8) 34 (2.6)
 Gentamicin (J01GB03) 265 (2.8) 151 (2.4) 62 (3.7) 46 (3.6)
 Sulfamethoxazole and trimethoprim (J01EE01) 235 (2.5) 66 (1.0) 7 (0.4) 150 (11.6)
 Clindamycin (J01FF01) 228 (2.4) 183 (2.9) 34 (2.1) 11 (0.9)
 Imipenem and enzyme inhibitor (J01DH51) 141 (1.5) 120 (1.9) 11 (0.7) 7 (0.5)
ATC: Anatomical Therapeutic Chemical; ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection.
The category “Unknown indication” represented 2.9% of the total and is included in the first column.
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Table 5
Antimicrobial use: prevalence, indication, route of administration and reason in patient charts/notes, ECDC pilot point 
prevalence survey, 2010 (n=6,875 patients)
Patients with antimicrobial usea Antimicrobial agents
n %b [95% CI] n Relative %c
Total 6,875 34.6 [33.8–35.4] 9,588 100
Indication
Treatment 4,500 22.6 [22.0–23.3] 6,365 66.4
Intended for community infection 2,919 14.7 [14.1–15.2] 3,957 41.3
Intended for hospital infection 1,539  7.7 [7.–-8.1] 2,300 24.0
Intended for other healthcare-associated infection 94  0.5 [0.4–0.6] 108 1.1
Surgical prophylaxis 1,396  7.0 [6.7–7.4] 1,654 17.3
Single dose 336  1.7 [1.5–1.9] 357 3.7
One day 265  1.3 [1.2–1.5] 293 3.1
More than one day 810  4.1 [3.8–4.4] 1,004 10.5
Medical prophylaxis 979  4.9 [4.6–5.2] 1,293 13.5
Unknown indication 211  1.1 [0.9–1.2] 276 2.9
Route of administration
Parenteral 5,098 25.6 [24.9–26.3] 6,891 71.9
Oral 2,218 11.2 [10.7–11.6] 2,648 27.6
Other/unknown 49  0.2 [0.2–0.3] 49 0.5
Reason in patient charts/notes
Yes 4,819 24.2 [23.6–24.9] 6,647 69.3
No 2,171 10.9 [10.5–11.4] 2,939 30.7
Unknown 2  0.0 [0.0–0.0] 2 0.0
CI: confidence interval; HAI: healthcare-associated infection.
a  Patients receiving a least one antimicrobial agent.    
b  Prevalence of antimicrobial use in each category.
c  Percentage of total number of antimicrobials (relative frequency).
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Table 6
Prevalence of healthcare-associated infections and antimicrobial use, by patient risk factors (standard patient-based protocol 
only, 50 hospitals), ECDC pilot point prevalence survey, 2010 (n=14,329)
Surveyed patients Patients with HAIsa Patients with antimicrobial useb
nc %d n %e n %e
All patients 14,329 100 1,072 7.5 5,201 36.3
Age group (years)
<1 746 5.2 58 7.8 181 24.3
1–4 267 1.9 18 6.7 135 50.6
5–14 393 2.7 12 3.1 148 37.7
15–24 699 4.9 30 4.3 228 32.6
25–34 1,224 8.5 34 2.8 313 25.6
35–44 1,160 8.1 75 6.5 385 33.2
45–54 1,527 10.7 106 6.9 570 37.3
55–64 2,325 16.2 212 9.1 939 40.4
65–74 2,582 18.0 241 9.3 1,012 39.2
75–84 2,481 17.3 202 8.1 903 36.4
≥85 925 6.5 84 9.1 387 41.8
Sex
Female 7,267 50.7 456 6.3 2,364 32.5
Male 7,062 49.3 616 8.7 2,837 40.2
Length of stay (days)f
1–3 4,622 32.3 104 2.3 1,352 29.3
4–7 3,916 27.3 300 7.7 1,608 41.1
8–14 2,824 19.7 272 9.6 1,137 40.3
>14 2,966 20.7 396 13.4 1,104 37.2
Surgical intervention since hospital admission
No 10,089 70.4 569 5.6 3,163 31.4
Yes 4,240 29.6 503 11.9 2,038 48.1
McCabe score
Non-fatal 9,705 67.7 491 5.1 3,088 31.8
Ultimately fatal 3,666 25.6 430 11.7 1,645 44.9
Rapidly fatal 791 5.5 143 18.1 419 53.0
Missing/unknown 167 1.2 8 4.8 49 29.3
Central vascular catheter
 No 12,621 88.1 651 5.2 4,033 32.0
 Yes 1,594 11.1 411 25.8 1,117 70.1
 Missing/unknown 114 0.8 10 8.8 51 44.7
Peripheral vascular catheter
 No 7,455 52.0 389 5.2 1,565 21.0
 Yes 6,763 47.2 674 10.0 3,592 53.1
 Missing/unknown 111 0.8 9 8.1 44 39.6
Urinary catheter
 No 11,702 81.7 612 5.2 3,594 30.7
 Yes 2,512 17.5 452 18.0 1,558 62.0
 Missing/unknown 115 0.8 8 7.0 49 42.6
Intubation
 No 13,734 95.8 888 6.5 4,775 34.8
 Yes 486 3.4 173 35.6 369 75.9
 Missing/unknown 109 0.8 11 10.1 57 52.3
ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection.
a  Patients with a least one HAI.
b  Patients receiving at least one antimicrobial agent.
c  Number of patients in category.     
d  Percentage of total (column percent).
e  Percentage within category (category percent).
f  Length of stay until onset of HAI in case of HAI during current hospitalisation.
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data collection and 1.3 for data entry. Eighteen hospi-
tals were surveyed by an external team (either national 
or regional coordination staff) (Table 7).
A large variation among responding countries was 
identified in the workload associated with the PPS. The 
calculation of workload included preparation and train-
ing before the actual PPS, as well as data collection 
and data entry. National PPS coordinators provided 
on average 12.4 hours (median: 6 hours) of training to 
the hospital staff and spent on average an additional 
6.5 hours (median: 4 hours) on answering questions 
during the survey. The time needed for collection and 
entry of data for 100 patients, was estimated at about 
four working days (ca. 32 hours) with the patient-based 
protocol and about 2.5 working days (ca. 20 hours) 
with the unit-based protocol. This means that perform-
ing the survey with the unit-based protocol took about 
37.5% less time than with the patient-based protocol. 
The feasibility of the data collection was also evaluated 
by the analysis of missing data in the database. At the 
national level, 11 of 23 countries were unable to provide 
national hospital denominator data by hospital type as 
defined in the protocol. At hospital level however, the 
hospital type was always available and the number 
of beds was only missing for one hospital. Ward level 
data were complete because all fields were mandatory 
in the software. Similarly, some patient level data (age, 
sex, hospital admission date and medical specialty of 
the patient’s disease or the consultant), infection data 
and antimicrobial use data were mandatory in the soft-
ware. For the other, non-mandatory variables of the 
patient-based protocol (n=14,329 patients), the per-
centage of missing values ranged from less than 1% 
for the presence of invasive devices, 1.2% for McCabe 
score, and 1.9% for surgery since admission, to 7.6% 
for surgery in the previous 30 days. 
Discussion
The ECDC pilot PPS of HAIs and antimicrobial use was 
successfully performed from May to October 2010 in 66 
acute care hospitals from 23 countries. In total, 19,888 
patients were surveyed. The number of participating 
hospitals was higher than the anticipated minimum of 
25 hospitals. The collected data allowed for the estima-
tion of the prevalence of HAIs and antimicrobial use, 
which was the primary objective set by ECDC. Both the 
patient-based protocol, preferred by the majority (76%) 
of hospitals, and the unit-based protocol (applied by 
24% of hospitals) provided the necessary data. 
Main study limitations
An important limitation of our study is that the hos-
pitals participating in this ECDC pilot PPS were not 
representative of the total hospital patient population 
in the EU. Hospitals were not randomly selected, and 
Table 7
Type of healthcare workers involved in data collection and data entry for the ECDC pilot point prevalence survey, 2010 
(n=50 hospitals)
Type of healthcare worker
Hospitals where this type of 
healthcare worker was involved
Involved in 
data collection
Involved in 
data entry
n %a n %b n % b
Infection control nurse 25 50 25 100 9 36
Infection control physician or equivalent 31 62 31 100 12 39
Ward nurse 18 36 18 100 0 0
Ward physician 15 30 15 100 0 0
Infectious disease physician 12 24 12 100 3 25
Hospital microbiologist 6 12 6 100 3 50
Medical specialist trainee 10 20 10 100 2 20
Hospital pharmacist 6 12 6 100 1 17
Infection control link nurse 5 10 5 100 1 20
Data nurse 4 8 3 75 2 50
Nurse aid 1 2 0 0 1 100
Medical student 1 2 1 100 0 0
Other hospital staff 10 20 6 60 6 60
National PPS coordination staff 13 26 12 92 6 46
Regional PPS coordination staff 5 10 5 100 2 40
Other 6 12 4 67 3 50
ECDC: European Centre for Disease Prevention and Control; PPS: point prevalence survey.
a  Percentage of total number of responding hospitals (n=50).
b  Percentage of number of healthcare workers in category.
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tertiary or teaching hospitals were overrepresented 
in the study sample (52.3% instead of less than 10%, 
according to available national hospital statistics). This 
selection had consequences both for the results of the 
feasibility test of the protocol and for the interpretation 
of the epidemiological results of the study (see below).
In addition, since inference from the epidemiological 
study results to the total acute care hospital population 
in Europe was not an objective of the pilot study, we did 
not apply any statistical methods that could take into 
account the effects of the hierarchical design of the 
study (e.g. regions within countries, hospitals within 
regions, wards within hospitals, and types of patients 
within wards). Methods such as multilevel modelling 
for risk factor analysis and complex survey analysis 
to adjust confidence intervals for the prevalence esti-
mates at the national and EU level will be used to ana-
lyse the EU-wide PPS of HAIs and antimicrobial use that 
was conducted in 2011–12. The pilot study database 
was also used to estimate the expected design effect 
(DEFF) for different average sizes of hospitals (patient 
clusters) in order to estimate the required sample size 
for each country in the EU-wide PPS [14]. The overall 
DEFF in the pilot PPS was 5.3 for the prevalence of HAIs 
and 22.7 for the prevalence of antimicrobial use, indi-
cating indeed that the sample design for representa-
tive samples at the national level should be adjusted 
for the important clustering of the main survey out-
comes within the hospitals. 
Feasibility study
A minority of respondents to the feasibility question-
naire mentioned that the participating included hospi-
tals in their country had had experience in performing 
PPSs and that it is unlikely that randomly selected hos-
pitals would be able to participate in an ECDC EU-wide 
PPS. ECDC therefore provided training material to help 
national contact points improve the skills of hospital 
staff during preparation of the future EU-wide PPS. Part 
of this training material was already available before 
the pilot PPS and was used to organise the training of 
the hospital contact points in the current study.
Training is also of key importance for the standardisa-
tion of data collection in participating hospitals, includ-
ing interpretation of the case definitions. The large 
variation in the number and type of HCWs involved in 
data collection for this pilot PPS (Table 7) illustrates 
the challenge of standardising data collection for an 
EU-wide PPS. For example, failure to consult the clini-
cal team in charge of patient care during data collec-
tion, as recommended in the protocol, may impact on 
the ascertainment of variables such as the medical 
specialty of the patient’s disease or of the consultant 
in charge of the patient (patient/consultant specialty), 
the McCabe score, the physician’s motive for prescrib-
ing antimicrobials, or even the signs and symptoms 
of a suspected HAI. The fact that ward staff was not 
involved in the data collection in more than half of the 
hospitals may indeed indicate that physicians were not 
sufficiently consulted. Also, the fact that in 18 of the 
66 hospitals the survey was performed by an external 
team may indicate that the pilot PPS was not always 
performed in real-life conditions since this scenario is 
unlikely to be a feasible option for the ECDC EU-wide 
PPS or a full-scale national PPS.
Another frequently mentioned feasibility issue was the 
difficulty to categorise hospitals at the national level 
according to the hospital types defined in the pro-
tocol (primary, secondary, tertiary and specialised). 
Information on hospital categories used in the differ-
ent countries are needed for the future EU-wide PPS to 
ensure that all categories are represented proportion-
ally in the national representative sample. In addition, 
national denominator data (e.g. number of hospitals 
and discharges per year) by hospital type would be 
needed (i) to extrapolate the PPS results by hospital 
type (category-specific burden estimates), and (ii) to 
adjust the national and EU burden estimates in case 
hospital types are not proportionally represented in 
the national samples. Only 13 of 23 countries were able 
to provide some categorisation of their national list of 
hospitals according to the categories of the protocol, 
using the national hospital type categories. 
Therefore, for the purpose of drawing a representative 
systematic sample of hospitals for the EU-wide PPS, 
the standardised EU types of hospitals were replaced 
by the national hospital categories in the final proto-
col of the ECDC EU-wide PPS. This means that, for the 
analysis of the data collected in the ECDC EU-wide PPS, 
it will not be possible to stratify or adjust the estimates 
of the burden of HAIs and antimicrobial use (based on 
extrapolation to the total national denominator data) 
according to types of hospitals. 
Patient-based versus unit-based protocol
Despite a higher workload, the patient-based protocol 
was used more often than the unit-based protocol, thus 
allowing a better description of patients and invasive 
procedures. During an expert meeting held in Brussels 
in November 2010, it was recommended that PPSs of 
HAIs and antimicrobial use should be carried out at 
least once every five years, and the patient-based pro-
tocol was selected as the preferred methodology for 
future PPSs [43]. This expert recommendation is antici-
pating the fact that, because of hospital changes and 
medical advances, a patient-based protocol would be 
required to allow for detailed adjustment for patient 
case-mix. The patient-based protocol allows for 
assessment of the prevalence of HAIs and antimicro-
bial use according to the presence or absence of vari-
ous risk factors and enables categorisation of hospitals 
by patient case-mix at national and/or European level. 
Indeed, adjustment for patient case-mix has been used 
in other studies, including for outcomes in intensive 
care [44,45] and surgical patients [46], and for com-
paring HAI rates [47]. Patient-based PPSs can also be 
used to identify patient-related factors that influence 
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the prevalence of HAIs and thus help focus surveillance 
and infection prevention initiatives [48]. 
The unit-based protocol, however, will be kept, to offer 
a less labour-intensive option for countries and hospi-
tals where human resources are limited. This protocol 
might also be more appropriate for very large hospitals 
and in situations that require repeated PPSs at short 
intervals. A limitation is that its only denominator vari-
able is the number of patients per ward, for the total 
ward and for the specialty of each patient’s disease 
within each ward. This only allows an estimation of the 
prevalence of HAIs and antimicrobial use by ward or 
patient’s disease specialty.
The ECDC pilot PPS also aimed at identifying any issue 
with the methodology that required modification, e.g. 
availability of data for any of the collected variables, 
or applicability of the case definitions for HAIs, before 
finalising the patient-based and unit-based protocols 
for the ECDC EU-wide PPS that was started in May 
2011. Denominator data in the unit-based protocol did 
not require any modification whereas, for the patient-
based protocol, the only variable that was difficult to 
obtain was ‘surgery in the previous 30 days’. This vari-
able also overlapped with ‘surgery since admission’ 
which was less difficult to determine. It was therefore 
decided that, for the ECDC EU-wide PPS, the data for 
the variable ‘surgery in previous 30 days’ would even-
tually not be collected [14]. With respect to case defini-
tions for HAIs, a major change was the decision to add 
the case definition of clinical sepsis in adults, because 
possible bloodstream infections for which microbiolog-
ical results were not yet available at the time of the PPS 
would otherwise remain unreported. 
Epidemiological results
The two sections of the ECDC pilot PPS, i.e. HAIs and 
antimicrobial use, were independent of each other and 
did not follow the same definitions: data on HAIs were 
recorded following standardised epidemiological case 
definitions, whilst the indication for antimicrobial use 
was based on clinical judgment by the treating physi-
cian. For example, a patient could have been registered 
in the antimicrobial use section as receiving antimicro-
bials with the intention to treat a hospital infection, 
but the same patient did not fulfil the case definition 
for HAI and therefore was not included as having a 
HAI in the HAI section. Conversely, a patient may have 
presented the symptoms and signs of a HAI, but not 
have been treated with an antimicrobial. Hence, among 
other things, the different proportions for hospital-
acquired pneumonia in Table 2. 
While the protocol for the EU-wide PPS foresees a rep-
resentative systematic random sample of hospitals 
in the participating countries [14], the data collected 
through this ECDC pilot PPS were not representative 
of the epidemiology of HAIs in the EU and the results 
must be interpreted with caution. The HAI prevalence 
of 7.1% (inter-quartile range: 4.2–9.4%) observed in 
our study is likely to be slightly overestimated because 
of the overrepresentation of tertiary hospitals which 
had a higher prevalence of HAIs (7.4%) than second-
ary and primary hospitals. Nevertheless, the overall 
HAI prevalence in this pilot PPS is comparable to that 
reported in other European studies [9,11,12] and to 
the European prevalence of HAIs of 7.1%, estimated 
by ECDC based on a review of 30 national or multicen-
tre PPSs in 19 countries in its Annual Epidemiological 
Report for 2008 [1]. The range of reported prevalence 
results in studies that used CDC definitions for HAIs 
in non-EU countries, ranged from 4.9% in Mauritius 
in 1992 to 19.1% in Malaysia in 2001 [30]. Such a wide 
range in the prevalence of HAIs could be explained by 
differences in methodology and patient case-mix, and 
should not immediately be interpreted as an indication 
of variations in performance. 
The distribution of isolated microorganisms in patients 
with HAI in this pilot PPS was also similar to that pre-
viously reported in the review of national or multicen-
tre point prevalence surveys, with E. coli being most 
frequent [1]. The fact that only 59.1% of the HAIs were 
documented by microbiological results was also in line 
with previous findings [9,49,50] and was expected 
because, with few exceptions, case definitions of HAIs 
are primarily based on clinical criteria. 
With respect to antimicrobial use, the ECDC pilot PPS 
showed a prevalence about 5% higher than shown by 
previous ESAC hospital PPSs using an identical meth-
odology [23,25,26]. Nevertheless, the ranking order of 
the most used antimicrobials was comparable to that 
observed in ESAC hospital PPSs, with the various beta-
lactams (penicillins, cephalosporins and carbapenems) 
accounting for more than half of all antimicrobials 
used. Other PPSs have reported a wide range of preva-
lence of antimicrobial use in acute care hospitals due 
to varying inclusion criteria [23]. 
A final aspect that should be considered for the inter-
pretation of the epidemiological results of this and 
future surveys is the fact that the ECDC pilot PPS was 
not performed on a single day. For feasibility reasons, 
hospitals were allowed to organise the PPS within a 
period of three weeks, with the only restriction being 
that a ward had to be surveyed on a single day. In prac-
tice, hospitals and countries performed the pilot PPS 
survey from May until October 2010. For the EU-wide 
PPS, ECDC agreed with the national PPS coordinat-
ing centres in November 2010 on three possible peri-
ods to organise the first national PPS using the ECDC 
methodology [43]. These periods (May–June 2011, 
September–October 2011 and May–June 2012) were 
selected to avoid the winter period because of the 
higher incidence of respiratory tract infections and the 
summer holiday period because shortage of staff and 
lower activity in the hospital during this period could 
influence the practical organisation as well as the main 
outcomes of the survey. Despite these considerations, 
the potentially long time span between the different 
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surveys may influence comparability of the results 
between hospitals, regions or countries, e.g. because 
of rapidly changing incidences of HAIs with epidemic 
pathogens or the implementation of local or national 
infection control measures. 
In conclusion, the ECDC pilot PPS methodology was suc-
cessfully implemented by the national contact points, 
the hospital contact points and the HCWs involved in 
data collection and entry in the participating hospitals, 
without any major feasibility issues that could have led 
hospitals to cancel their participation. The pilot PPS 
showed that the aim of estimating the burden of HAIs 
and antimicrobial use in European acute care hospitals 
was realistic, irrespective of the protocol used. The 
patient-based protocol, even if more resource-inten-
sive, was used more widely and provided more detailed 
and valuable data than the unit-based protocol. It was 
therefore selected as the preferred option for the ECDC 
EU-wide PPS of HAIs and antimicrobial use. 
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